CAMP · Insider Trading
CAMP4 Therapeutics Corporation Common Stock
Every open-market purchase and sale reported by CAMP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Kelly Gold | Chief Financial Officer | Buy | +10,000 | +$39.60K |
| 2026-08-31 | Andrew J. Schwab | Director | Sell | −400,000 | −$1.62M |
| 2026-08-26 | Andrew J. Schwab | Director | Sell | −10 | −$45 |
| 2026-08-21 | Andrew J. Schwab | Director | Sell | −191,865 | −$879.72K |
| 2026-08-19 | Daniel Tardiff | Chief Scientific Officer | Sell | −1,738 | −$8.27K |
| 2026-08-05 | Josh Mandel-Brehm | Chief Executive Officer | Buy | +6,551 | +$10.81K |
| 2026-08-05 | Richard A Young | Director | Buy | +16,378 | +$27.02K |
| 2026-08-05 | Andrew J. Schwab | Director | A | +3,179,558 deriv. | — |
| 2026-08-05 | 5AM Ventures VII, L.P. | 10%+ Owner | Buy | +22,256,906 deriv. | — |
| 2026-08-05 | Kelly Gold | Chief Financial Officer | Buy | +6,551 | +$10.81K |
| 2026-08-05 | Yuri Maricich | Chief Medical Officer | Buy | +6,551 | +$10.81K |
| 2026-06-12 | Andrew J. Schwab | Director | A | +28,000 deriv. | — |
| 2026-06-12 | Amir Nashat | Director | A | +28,000 deriv. | — |
| 2026-06-12 | Richard A Young | Director | A | +28,000 deriv. | — |
| 2026-06-12 | Douglas E Williams | Director | A | +28,000 deriv. | — |
| 2026-06-12 | Steven H Holtzman | Director | A | +28,000 deriv. | — |
| 2026-06-12 | Murray Stewart | Director | A | +28,000 deriv. | — |
| 2026-04-03 | Kelly Gold | Chief Financial Officer | A | +215,000 deriv. | — |
| 2026-04-03 | Josh Mandel-Brehm | Chief Executive Officer | A | +580,000 deriv. | — |
| 2026-04-03 | Yuri Maricich | Chief Medical Officer | A | +215,000 deriv. | — |
| 2026-04-03 | Michael F MacLean | Director | A | +56,000 deriv. | — |
| 2026-04-03 | Daniel Tardiff | Chief Scientific Officer | A | +170,000 deriv. | — |
| 2025-12-22 | Kelly Gold | Chief Financial Officer | A | +190,000 deriv. | — |
| 2025-12-22 | Josh Mandel-Brehm | Chief Executive Officer | A | +425,000 deriv. | — |
| 2025-12-22 | Yuri Maricich | Chief Medical Officer | A | +190,000 deriv. | — |
| 2025-12-22 | Daniel Tardiff | Chief Scientific Officer | A | +145,500 deriv. | — |
| 2025-09-15 | Andrew J. Schwab | Director | A | +2,941,176 | +$4.50M |
| 2025-09-15 | 5AM Ventures VI, L.P. | 10%+ Owner | Buy | +20,588,232 | +$31.50M |
| 2025-09-11 | Kelly Gold | Chief Financial Officer | Buy | +6,060 | +$10.00K |
| 2025-09-11 | Amir Nashat | Director | Buy | +1,307,189 | +$2.00M |
| 2025-09-11 | Josh Mandel-Brehm | Chief Executive Officer | Buy | +6,060 | +$10.00K |
| 2025-09-11 | Richard A Young | Director | Buy | +15,151 | +$25.00K |
| 2025-09-11 | Yuri Maricich | Chief Medical Officer | Buy | +6,060 | +$10.00K |
| 2025-09-11 | Brian Chee | 10%+ Owner | Buy | +9,150,323 | +$14.00M |
| 2025-06-27 | Paula Ragan | Director | A | +9,000 deriv. | — |
| 2025-06-27 | Steven H Holtzman | Director | A | +9,000 deriv. | — |
| 2025-06-27 | James P Boylan | Director | A | +9,000 deriv. | — |
| 2025-06-27 | Ravi I. Thadhani | Director | A | +9,000 deriv. | — |
| 2025-06-27 | Andrew J. Schwab | Director | A | +9,000 deriv. | — |
| 2025-06-27 | Amir Nashat | Director | A | +9,000 deriv. | — |
| 2025-06-27 | Richard A Young | Director | A | +9,000 deriv. | — |
| 2025-06-27 | Michael J Higgins | Director | A | +9,000 deriv. | — |
| 2025-04-03 | Yuri Maricich | Chief Medical Officer | A | +80,000 deriv. | — |
| 2025-04-03 | David Bumcrot | Chief Scientific Officer | A | +45,000 deriv. | — |
| 2025-04-03 | Kelly Gold | Chief Financial Officer | A | +80,000 deriv. | — |
| 2025-04-03 | Josh Mandel-Brehm | Chief Executive Officer | A | +160,000 deriv. | — |
| 2025-03-19 | Murray Stewart | Director | A | +17,787 deriv. | — |
| 2025-03-19 | Douglas E Williams | Director | A | +17,787 deriv. | — |
| 2024-10-22 | Polaris Management Co. VII, L.L.C. | 10%+ Owner | MIXED | +18,375,434 | +$70.00M |
| 2024-10-17 | Enavate Sciences GP, LLC | 10%+ Owner | MIXED | +7,571,604 | +$30.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| 5AM Ventures VI, L.P. | 10%+ Owner | 2,941,176 | $11.53M |
| Enavate Sciences GP, LLC | 10%+ Owner | 2,422,166 | $9.49M |
| Andrew J. Schwab | Director | 2,033,270 | $7.97M |
| AH Equity Partners Bio IV, L.L.C. | 10%+ Owner | 1,579,885 | $6.19M |
| Brian Chee | 10%+ Owner | 909,090 | $3.56M |
| Michael P. Rubin | 10%+ Owner | 763,636 | $2.99M |
| 5AM Opportunities II (GP), LLC | 10%+ Owner | 302,770 | $1.19M |
| Josh Mandel-Brehm | Chief Executive Officer | 284,968 | $1.12M |
| Amir Nashat | Director | 197,661 | $774.83K |
| Richard A Young | Director | 186,388 | $730.64K |
| Amy W Schulman | 10%+ Owner | 112,193 | $439.80K |
| Polaris Management Co. VII, L.L.C. | 10%+ Owner | 112,193 | $439.80K |
| Steven H Holtzman | Director | 108,946 | $427.07K |
| Kelly Gold | Chief Financial Officer | 86,467 | $338.95K |
| Yuri Maricich | Chief Medical Officer | 12,611 | $49.44K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CAMP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.